SCM
PBYI icon

Sterling Capital Management’s Puma Biotechnology PBYI Stock Holding History

Sterling Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.74K Sell
831
-594
-42% -$4.35K ﹤0.01% 2451
2026
Q1 		$9.11K Sell
1,425
-1,057
-43% -$6.82K ﹤0.01% 2420
2025
Q4 		$14.8K Sell
2,482
-445
-15% -$2.36K ﹤0.01% 2397
2025
Q3 		$15.5K Buy
2,927
+1,782
+156% +$7.56K ﹤0.01% 2258
2025
Q2 		$3.93K Buy
1,145
+640
+127% +$2.04K ﹤0.01% 2642
2025
Q1 		$1.5K Sell
505
-421
-45% -$1.32K ﹤0.01% 2685
2024
Q4 		$2.82K Buy
926
+826
+826% +$2.4K ﹤0.01% 2666
2024
Q3 		$255 Buy
+100
New +$303 ﹤0.01% 3073
2015
Q2 		– Sell
-1,496
Closed -$353K – 922
2015
Q1 		$353K Buy
+1,496
New +$320K ﹤0.01% 758

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's PBYI Position: Q2 2026 in Review

Sterling Capital Management reduced its Puma Biotechnology (PBYI) stake by 42% in Q2 2026, selling an estimated $4.35K and leaving 831 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Sterling Capital Management first reported a position in PBYI in Q1 2015 and has held it in 9 quarters since. The position peaked at $353K in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Sterling Capital Management held 831 shares of Puma Biotechnology worth $6.74K as of Q2 2026.
  • Sterling Capital Management sold 594 Puma Biotechnology shares in Q2 2026, an estimated $4.35K.
  • Puma Biotechnology made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2451 holding.
  • Sterling Capital Management first reported a position in Puma Biotechnology in Q1 2015 and has held it in 9 quarters since.
  • Sterling Capital Management's Puma Biotechnology position peaked at $353K in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.